Medicine prices are a contentious issue, with many products arguably unaffordable, even in developed countries, where, on average,
approximately 10% of the health budget is spent on medicines. But in low- and middle-income countries, that figure is usually
substantially higher, and a sizeable proportion of the population usually pays for medicines out of pocket, thereby reflecting
both limited resources and generally inefficient public health systems. High out-of-pocket costs disproportionally affect the
economically disadvantaged and are more likely to impair patient access to effective treatments in poorer communities.
In Ukraine a significant proportion of health services are delivered in facilities owned and managed at the district (oblast) level. Those facilities are responsible for the procurement and management of all medicines and medical products that are not supplied within the eighteen national programs. The effectiveness and transparency of implementing regulations, as well as of procurement and related activities, have a decisive effect on medicine prices. The motivation for this site is to offer reliable, meaningful, and up-to-date information to the public to help them leverage for better pricing and more transparent procurement procedures.
The site aggregates information on the prices of twenty medicines to serve as a tracer on how prices behave in the Ukrainian pharmaceutical market. Information from a set of benchmark countries is used to offer a balanced view on how those compare to international reference prices, and including an indicator on public "value-for-money" (cost-effectiveness). Furthermore, Ukrainian price is geographically and temporally stamped to allow for time-series and regional comparisons. Lastly, following HAI/WHO methodology, prices are not only displayed in the local currency, but also in terms of patient affordability, by using the lowest-paid public employee salary as the basis for calculating one-month worth of treatment for every commodity.